Genetically Engineered T Cells for Agricultural Pest Control and Environmental Applications

Publication ID: 24-11857574_0002_PTD
Published: October 28, 2025
Category:New Applications & Use Cases

Legal Citation

pr1or.art Inc., “Genetically Engineered T Cells for Agricultural Pest Control and Environmental Applications,” Published Technical Disclosure No. 24-11857574_0002_PTD, Published October 28, 2025, available at https://archive.pr1or.art/24-11857574_0002_PTD
This technical disclosure describes improvements that would be readily apparent to a Person Having Ordinary Skill In The Art (PHOSITA) when considered in combination with the foundational architecture disclosed in U.S. Patent No. 11,857,574.

Summary of the Inventive Concept

This inventive concept leverages the core technology of genetically engineered T cells with Regnase-1 and/or TGFBRII disruption to develop novel applications in agricultural pest control, environmental monitoring, and bioremediation, offering a new paradigm for sustainable and targeted solutions.

Background and Problem Solved

The original patent disclosed genetically engineered T cells with improved functionality and persistence for cancer treatment. However, the limitations of this technology in addressing other pressing issues, such as agricultural pest control and environmental pollution, were not fully explored. This inventive concept addresses these gaps by applying the core technology to new, non-obvious applications.

Detailed Description of the Inventive Concept

The inventive concept involves genetically engineering T cells with Regnase-1 and/or TGFBRII disruption to target specific pest species, enhance plant defense mechanisms, detect environmental pollutants, and facilitate bioremediation. These T cells can be engineered to express specific receptors or antigens, allowing them to selectively target and eliminate pests or pathogens. The CRISPR/Cas-mediated gene editing system can be used to introduce the desired genetic modifications. The resulting T cells can be administered to plants, soil, or water to achieve the desired effects.

Novelty and Inventive Step

The novelty of this inventive concept lies in the unexpected application of genetically engineered T cells with Regnase-1 and/or TGFBRII disruption to non-cancer, non-human health-related fields. The inventive step involves recognizing the potential of this technology to address pressing environmental and agricultural challenges, and developing new, non-obvious uses for the core technology.

Alternative Embodiments and Variations

Alternative embodiments of this inventive concept could include using different gene editing systems, such as TALEN or ZFN, or engineering T cells to target specific disease-causing pathogens in plants or animals. Variations could also involve using the T cells in combination with other technologies, such as precision agriculture or bioreactors, to enhance their effectiveness.

Potential Commercial Applications and Market

The potential commercial applications of this inventive concept are vast, with potential markets in agricultural pest control, environmental monitoring, and bioremediation. The technology could be licensed to companies developing sustainable agricultural practices, environmental monitoring systems, or bioremediation solutions, offering a new revenue stream and opportunities for growth.

Original Patent Information

Patent NumberUS 11,857,574
TitleGenetically engineered T cells with Regnase-1 and/or TGFBRII disruption have improved functionality and persistence
Assignee(s)CRISPR THERAPEUTICS AG